Outcome of deferred initial therapy in mantle-cell lymphoma

Journal of Clinical Oncology

Volumn 27, Issue 8, 2009, Pages 1209-1213

  Martin, Peter ^a   Chadburn, Amy ^a   Christos, Paul ^a   Weil, Karen ^a   Furman, Richard R ^a   Ruan, Jia ^a   Elstrom, Rebecca ^a   Niesvizky, Ruben ^a   Ely, Scott ^a   Diliberto, Maurizio ^a   Melnick, Ari ^a   Knowles, Daniel M ^a   Chen Kiang, Selina ^a   Coleman, Morton ^a   Leonard, John P ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; PROTEIN P53; VINCRISTINE;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; DEATH; DEFERRED INITIAL THERAPY; EARLY TREATMENT; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; METASTASIS; OBSERVATION; OVERALL SURVIVAL; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; THERAPY DELAY; TIME TO TREATMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PREDNISOLONE; PROGNOSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84862194194     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.6121     Document Type: Article

References (28)

1. Berard CW, Dorfman RF: Histopathology of malignant lymphomas. Clin Haematol 3:39-76, 1974
2. Harris NL, Jaffe ES, Stein H, et al: A revised European-American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
3. Lennert K, Feller A: Histopathology of Non-Hodgkin's Lymphomas Based on the Kiel Classification (ed 2). New York, NY, Springer-Verlag, 1992
4. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
5. Stein H, Mann R, Delsol G: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001
6. Vandenberghe E, De Wolf-Peeters C, Vaughan Hudson G, et al: The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol 99:842-847, 1997
7. Zucca E, Roggero E, Pinotti G, etal: Patterns of survival in mantle cell lymphoma. Ann Oncol 6:257-262, 1995
8. Fisher Rl, Dahlberg S, Nathwani BN, et al: A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories)-A Southwest Oncology Group study. Blood 85:1075-1082, 1995
9. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al: Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes-European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 13:2819-2826, 1995
10. Argatoff LH, Connors JM, Klasa RJ, et al: Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood 89:2067-2078, 1997
11. Ganti AK, Bierman PJ, Lynch JC, et al: Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 16:618-624, 2005
12. Romaguera JE, Fayad L, Rodriguez MA, et al: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytara-bine. J Clin Oncol 23:7013-7023, 2005
13. 13.Kahl BS, Longo WL, Eickhoff JC, et al: Maintenance rituximab following induction che-moimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. Ann Oncol 17:1418-1423, 2006
14. Gianni AM, Magni M, Martelli M, et al: Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102:749-755, 2003
15. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 105:2677-2684, 2005
16. Determann O, Hoster E, Ott G, et al: Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immun-ochemotherapy: Results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111:2385-2387, 2008
17. 53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87:4302-4310, 1996
18. 53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87:3351-3359, 1996
19. Hoster E, Dreyling M, KlapperW, et al: A new prognostic index (MlPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565,2008
20. Solal-Celigny P, Roy P, Colombat P, et al: Follicular Lymphoma International Prognostic Index. Blood 104:1258-1265, 2004
21. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
22. osenwald A, Wright G, Wiestner A, et al: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts urvival in mantle cell lymphoma. Cancer Cell 3:185-197, 2003
23. eonard JP, Furman RR, Cheung Y-KK, et al: Phase l/ll trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): Phase I results. Am Soc Hematol Annu Meet Abstracts 106:491, 2005 (abstr 491)
24. affe ES, Harris NL, Stein H, et al: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001
25. Advani R, Rosenberg SA, Horning SJ: Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. J Clin Oncol 22:1454-1459, 2004
26. owper DC, Kubal JD, Maynard C, et al: A primer and comparative review of major US mortality databases. Ann Epidemiol 12:462-468, 2002
27. Salaverria I, Zettl A, Bea S, et al: Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 25:1216-1222, 2007
28. 28.Kienle D, Katzenberger T, Ott G, et al: Quantitative gene expression deregulation in mantle-cell lymphoma: Correlation with clinical and biologic factors. J Clin Oncol 25:2770-2777, 2007